Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression

Lipid metabolism disturbances are linked to the development of atherosclerosis (AS), with arachidonic acid (AA) and other downstream metabolites being involved. Cytosolic phospholipase A2 (cPLA2) is a key restriction enzyme in AA metabolism. Salidroside (SAL) reportedly alleviates AS by inhibiting i...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing Liao, Yihua Wang, Rong Huang, Ailu Deng, Han Xu, Wen Guo, Dan Wen, Tianqin Xia, Jiaojiao Bian, Zhengmin Xu, Chunyang Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:All Life
Subjects:
Online Access:http://dx.doi.org/10.1080/26895293.2025.2515449
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850209858636218368
author Qing Liao
Yihua Wang
Rong Huang
Ailu Deng
Han Xu
Wen Guo
Dan Wen
Tianqin Xia
Jiaojiao Bian
Zhengmin Xu
Chunyang Zhou
author_facet Qing Liao
Yihua Wang
Rong Huang
Ailu Deng
Han Xu
Wen Guo
Dan Wen
Tianqin Xia
Jiaojiao Bian
Zhengmin Xu
Chunyang Zhou
author_sort Qing Liao
collection DOAJ
description Lipid metabolism disturbances are linked to the development of atherosclerosis (AS), with arachidonic acid (AA) and other downstream metabolites being involved. Cytosolic phospholipase A2 (cPLA2) is a key restriction enzyme in AA metabolism. Salidroside (SAL) reportedly alleviates AS by inhibiting inflammation and slowing cholesterol accumulation; however, its pharmacological action on lipid metabolism remains unclear. We investigated the effects of SAL on AA metabolism and its interaction with cPLA2 in in vivo and in vitro AS models. SAL inhibited lipid accumulation and atherosclerotic plaque formation, reduced M1 macrophage enrichment in the aortic arch, and decreased cPLA2 expression in both models. Interestingly, the prediction and molecular dynamics (MD) analysis of small molecules indicated that SAL may bind to the cPLA2 protein with high affinity, enhancing its stability and flexibility, and inhibiting its activity. The AA metabolome was disordered in PBS-treated AS mice; with 27 metabolites being significantly different from those in SAL-treated mice, including 15-HETE produced by 15-Lox-2. Moreover, knockdown of 15-Lox-2 in macrophages increased lipid accumulation and cPLA2 expression, which were inhibited by SAL. In summary, SAL affects AS by regulating the disordered metabolism of AA in AS, directly binding to cPLA2, and modulating the function of downstream enzymes of AA.
format Article
id doaj-art-0ba7922f7b844abcb464a69c48e5869c
institution OA Journals
issn 2689-5307
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series All Life
spelling doaj-art-0ba7922f7b844abcb464a69c48e5869c2025-08-20T02:09:55ZengTaylor & Francis GroupAll Life2689-53072025-12-0118110.1080/26895293.2025.25154492515449Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progressionQing Liao0Yihua Wang1Rong Huang2Ailu Deng3Han Xu4Wen Guo5Dan Wen6Tianqin Xia7Jiaojiao Bian8Zhengmin Xu9Chunyang Zhou10Institute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeInstitute of Materia Medica, North Sichuan Medical CollegeLipid metabolism disturbances are linked to the development of atherosclerosis (AS), with arachidonic acid (AA) and other downstream metabolites being involved. Cytosolic phospholipase A2 (cPLA2) is a key restriction enzyme in AA metabolism. Salidroside (SAL) reportedly alleviates AS by inhibiting inflammation and slowing cholesterol accumulation; however, its pharmacological action on lipid metabolism remains unclear. We investigated the effects of SAL on AA metabolism and its interaction with cPLA2 in in vivo and in vitro AS models. SAL inhibited lipid accumulation and atherosclerotic plaque formation, reduced M1 macrophage enrichment in the aortic arch, and decreased cPLA2 expression in both models. Interestingly, the prediction and molecular dynamics (MD) analysis of small molecules indicated that SAL may bind to the cPLA2 protein with high affinity, enhancing its stability and flexibility, and inhibiting its activity. The AA metabolome was disordered in PBS-treated AS mice; with 27 metabolites being significantly different from those in SAL-treated mice, including 15-HETE produced by 15-Lox-2. Moreover, knockdown of 15-Lox-2 in macrophages increased lipid accumulation and cPLA2 expression, which were inhibited by SAL. In summary, SAL affects AS by regulating the disordered metabolism of AA in AS, directly binding to cPLA2, and modulating the function of downstream enzymes of AA.http://dx.doi.org/10.1080/26895293.2025.2515449salidrosideatherosclerosiscpla2arachidonic acid
spellingShingle Qing Liao
Yihua Wang
Rong Huang
Ailu Deng
Han Xu
Wen Guo
Dan Wen
Tianqin Xia
Jiaojiao Bian
Zhengmin Xu
Chunyang Zhou
Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
All Life
salidroside
atherosclerosis
cpla2
arachidonic acid
title Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
title_full Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
title_fullStr Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
title_full_unstemmed Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
title_short Salidroside targeted cytosolic phospholipase A2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
title_sort salidroside targeted cytosolic phospholipase a2 and regulated arachidonic acid metabolomics to attenuate atherosclerosis progression
topic salidroside
atherosclerosis
cpla2
arachidonic acid
url http://dx.doi.org/10.1080/26895293.2025.2515449
work_keys_str_mv AT qingliao salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT yihuawang salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT ronghuang salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT ailudeng salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT hanxu salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT wenguo salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT danwen salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT tianqinxia salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT jiaojiaobian salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT zhengminxu salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression
AT chunyangzhou salidrosidetargetedcytosolicphospholipasea2andregulatedarachidonicacidmetabolomicstoattenuateatherosclerosisprogression